<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the development of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e>, the current study examined changes in peripheral axonal function </plain></SENT>
<SENT sid="1" pm="."><plain>Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (<z:chebi fb="7" ids="53203">NCS</z:chebi>), HbA(1c) levels, and total <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> score (TNS) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were categorized into two cohorts: patients with <z:mp ids='MP_0002055'>diabetes</z:mp> without <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (DWN group [n = 56]) and patients with <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (DN group [n = 52]) and further into severity grade 0 (TNS 0-1 [n = 35]), grade 1 (TNS 2-8 [n = 42]), and grade 2/3 (TNS 9-24 [n = 31]) </plain></SENT>
<SENT sid="3" pm="."><plain>Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus </plain></SENT>
<SENT sid="5" pm="."><plain>Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest a spectrum of excitability abnormalities in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and that early axonal dysfunction may be detected prior to the development of <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>As progressive changes in excitability parameters correlated to <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> severity, excitability testing may provide a biomarker of the early development and severity of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e>, providing insights into the pathophysiological mechanisms producing axonal dysfunction </plain></SENT>
</text></document>